IO Biotech, Inc.
IOBTDelisted Jun 8, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001865494
IO Biotech, Inc. was delisted on Jun 8, 2026; its insiders filed their last Form 4 on Jun 6, 2025; 12 institutions reported holding it in 13F filings for Q1 2026, worth $199.0K in total; no superinvestor held it.
13F holders, Q1 2025
Institutional positions in IO Biotech, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- −5 vs. Q4 2024
- Shares held
- 19.1M
- −626.2K (−3.2%) vs. Q4 2024
- Total value
- $20.8M
- +$2.67M (+14.7%) vs. Q4 2024
- New holders
- 1
- 3 more added
- Sold out
- 6
- 8 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IOBT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 12 | $199.0K |
| Q4 2025 | 22 | $4.78M |
| Q3 2025 | 21 | $3.59M |
| Q2 2025 | 26 | $25.3M |
| Q1 2025 | 22 | $20.8M |
| Q4 2024 | 27 | $18.2M |
| Q3 2024 | 20 | $24.8M |
| Q2 2024 | 20 | $30.7M |
| Q1 2024 | 18 | $47.4M |
| Q4 2023 | 18 | $55.3M |
| Q3 2023 | 19 | $41.7M |
| Q2 2023 | 15 | $24.0M |
| Q1 2023 | 17 | $26.1M |
| Q4 2022 | 17 | $32.8M |
| Q3 2022 | 21 | $41.6M |
| Q2 2022 | 18 | $72.2M |
| Q1 2022 | 19 | $76.9M |
| Q4 2021 | 20 | $92.6M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding IO Biotech, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| SBI Securities Co., Ltd. | 130 | $142 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 12,355 | $13.5K | 0.00% | −34,675−73.7% | Reduced |
| Vontobel Holding Ltd. | 20,029 | $21.8K | 0.00% | −12,638−38.7% | Reduced |
| Jane Street Group, LLC | 23,717 | $25.9K | 0.00% | +23,717 | New |
| Acadian Asset Management LLC | 30,858 | $33.0K | 0.00% | −29,792−49.1% | Reduced |
| Geode Capital Management, LLC | 33,307 | $36.3K | 0.00% | 00.0% | Unchanged |
| Marex Group plc | 45,000 | $49.0K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 45,555 | $49.7K | 0.00% | −224,949−83.2% | Reduced |
| XTX Topco Ltd | 50,486 | $55.0K | 0.00% | +22,446+80.0% | Added |
| Bridgeway Capital Management, LLC | 75,000 | $81.8K | 0.00% | −99,000−56.9% | Reduced |
| Sectoral Asset Management Inc | 95,000 | $103.5K | 0.08% | +20,000+26.7% | Added |
| Renaissance Technologies LLC | 126,400 | $137.8K | 0.00% | +7,600+6.4% | Added |
| Soleus Capital Management, L.P. | 192,670 | $210.0K | 0.02% | 00.0% | Unchanged |
| Landscape Capital Management, L.L.C. | 400,234 | $436.3K | 0.04% | −41,962−9.5% | Reduced |
| Dauntless Investment Group, LLC | 681,446 | $742.8K | 2.74% | −66,200−8.9% | Reduced |
| Morgan Stanley | 789,461 | $860.5K | 0.00% | −69,714−8.1% | Reduced |
| Pivotal bioVenture Partners Investment Advisor LLC | 864,197 | $942.0K | 0.76% | 00.0% | Unchanged |
| Bank of America Corp | 1,651,515 | $1.80M | 0.00% | 00.0% | Unchanged |
| Marshall Wace, LLP | 2,105,262 | $2.29M | 0.00% | 00.0% | Unchanged |
| PFM Health Sciences, LP | 2,341,107 | $2.55M | 0.20% | 00.0% | Unchanged |
| Novo Holdings A/S | 3,354,449 | $3.66M | 0.28% | 00.0% | Unchanged |
| Vivo Capital, LLC | 6,173,439 | $6.73M | 0.89% | 00.0% | Unchanged |
| Royal Bank of Canada | 0 | $0 | 0.00% | −60,000−100.0% | Sold out |
| Wealth Enhancement Advisory Services, LLC | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| PKS Advisory Services, LLC | 0 | $0 | 0.00% | −16,000−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −12,384−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −12,689−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −5−100.0% | Sold out |